Owkin Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
325
- Latest Deal Type
-
Later Stage VC
- Investors
-
24
Owkin General Information
Description
Developer of an artificial intelligence agent system intended to analyze biological patient data and to support drug discovery and clinical research. The company offers artificial intelligence research agents, biological data analysis tools, digital pathology diagnostics, drug discovery software, clinical research analytics, and biomedical knowledge agents, enabling pharmaceutical companies and researchers to analyze patient data, identify drug candidates, and support clinical trial development.
Contact Information
Website
www.owkin.comCorporate Office
- 14/16 Bd Poissonnière
- 75009 Paris
- France
Corporate Office
- 14/16 Bd Poissonnière
- 75009 Paris
- France
Owkin Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC | 31-Dec-2024 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series B1) | 09-Jun-2022 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series B) | 18-Nov-2021 | Completed | Generating Revenue | |||
| 7. Accelerator/Incubator | 22-Jun-2021 | Completed | Generating Revenue | |||
| 6. Early Stage VC (Series A3) | 06-May-2020 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series A2) | 07-Mar-2019 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 23-May-2018 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 20-Mar-2018 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 02-Nov-2017 | $2.1M | Completed | Generating Revenue | ||
| 1. Seed Round | 01-Oct-2016 | $2.1M | $2.1M | Completed | Startup |
Owkin Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B | ||||||||
| Series A3 | ||||||||
| Series A2 | ||||||||
| Series A | 5,936,265 | $0.000100 | $2.7 | $2.7 | 1x | $2.7 | 16.49% | |
| Seed | 3,589,861 | $0.000100 | $0.59 | $0.59 | 1x | $0.59 | 9.97% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Owkin Comparisons
Industry
Financing
Details
Owkin Competitors (18)
One of Owkin’s 18 competitors is PathAI, a Venture Capital-Backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| PathAI | Venture Capital-Backed | Boston, MA | ||||
| NuMedii | Formerly VC-backed | San Mateo, CA | ||||
| Genesis Molecular AI | Venture Capital-Backed | San Mateo, CA | ||||
| ConcertAI | Private Equity-Backed | Cambridge, MA | ||||
| Paige | Formerly VC-backed | New York, NY |
Owkin Patents
Owkin Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025085632-A1 | Federated external control arms method for privacy-enhanced causal inference on distributed data | Inactive | 20-Oct-2023 | ||
| EP-4627523-A1 | Systems and methods for detecting tertiary lymphoid structures | Pending | 30-Nov-2022 | ||
| EP-4627523-A4 | Systems and methods for detecting tertiary lymphoid structures | Pending | 30-Nov-2022 | ||
| US-20260359976-A1 | Systems and methods for detecting tertiary lymphoid structures | Pending | 30-Nov-2022 | ||
| WO-2024118842-A1 | Systems and methods for detecting tertiary lymphoid structures | Inactive | 30-Nov-2022 | G06V10/82 |
Owkin Signals
Owkin Investors (24)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bridford Group | Venture Capital | Minority | ||
| Top Harvest Capital | Venture Capital | Minority | ||
| Bristol-Myers Squibb | Corporation | Minority | ||
| Key Ventures | Venture Capital | Minority | ||
| Sanofi | Corporation | Minority |
Owkin Investments (2)
Owkin’s most recent deal was a Early Stage VC with Bioptimus for . The deal was made on 19-Feb-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Bioptimus | 19-Feb-2024 | Early Stage VC | Discovery Tools (Healthcare) | ||
| Tribun Health | 01-Dec-2022 | Later Stage VC | Diagnostic Equipment |
Owkin FAQs
-
When was Owkin founded?
Owkin was founded in 2016.
-
Where is Owkin headquartered?
Owkin is headquartered in Paris, France.
-
What is the size of Owkin?
Owkin has 325 total employees.
-
What industry is Owkin in?
Owkin’s primary industry is Discovery Tools (Healthcare).
-
Is Owkin a private or public company?
Owkin is a Private company.
-
What is Owkin’s current revenue?
The current revenue for Owkin is .
-
How much funding has Owkin raised over time?
Owkin has raised $334M.
-
Who are Owkin’s investors?
Bridford Group, Top Harvest Capital, Bristol-Myers Squibb, Key Ventures, and Sanofi are 5 of 24 investors who have invested in Owkin.
-
Who are Owkin’s competitors?
PathAI, NuMedii, Genesis Molecular AI, ConcertAI, and Paige are some of the 18 competitors of Owkin.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process